Sugammadex vs. Neostigmine: New Evidence on Post-Anesthesia Recovery

Why Reversal Drugs Matter After Anesthesia

General anesthesia is used in hundreds of millions of surgeries each year, and neuromuscular blocking agents (NMBAs) are essential for safe intubation and good surgical conditions.

When the effects of NMBAs persist after surgery, patients may experience residual neuromuscular blockade (RNB). RNB has been associated with postoperative pulmonary complications, higher mortality, longer hospital stays, increased healthcare costs, and a greater overall medical burden.

Even mild residual weakness can reduce respiratory function, swallowing ability, and airway protection. These issues are especially concerning in older patients, who face a higher risk of pneumonia, aspiration, and atelectasis. Preventing RNB is therefore a central safety goal in modern anesthesia practice.

Neostigmine and Sugammadex: Two Different Strategies

Neostigmine, a cholinesterase inhibitor, has long been the standard reversal agent. It can accelerate recovery from neuromuscular block, but residual blockade still occurs in around 40% of patients after neostigmine. This leaves many patients exposed to avoidable postoperative risk.

Sugammadex, introduced in 2008, represents a different approach. It is a gamma-cyclodextrin that selectively binds to rocuronium, allowing rapid and complete reversal of neuromuscular blockade without negatively affecting upper airway dilator muscles. Studies have shown that sugammadex is more effective than neostigmine in achieving a Train-of-Four ratio (TOFR) greater than 0.9, a commonly used threshold for safe neuromuscular recovery.

Despite these advantages, the broader clinical impact of sugammadex has remained uncertain. Existing studies and meta-analyses have focused on selected outcomes such as pulmonary complications, PONV, or TOF recovery, often with inconclusive or conflicting results. Important questions remained about high-risk groups, overall recovery, and cognitive outcomes.

The Aim and Scale of the New Meta-Analysis

To address these gaps, Ni Zhu and Yongli Li conducted a systematic review and meta-analysis comparing sugammadex and neostigmine in surgical patients recovering from general anesthesia.

They describe their goal as:

“This study systematically evaluates the impact of neuromuscular blockade antagonists on postoperative complications and quality of recovery in surgical patients.”

The authors searched major medical databases up to April 2025 and applied predefined inclusion criteria. In total, they included:

• 35 randomized controlled trials (4,275 patients)

• 2 retrospective studies (49,642 participants)

The analysis focused on patients receiving general anesthesia who required reversal of neuromuscular blockade. For sugammadex trials, the comparator was neostigmine; for neostigmine trials, the comparator was either placebo or standard care without an active reversal agent.

The outcomes covered several domains: speed of reversal, postoperative complications, recovery time, cognitive function, and 30-day readmission. Subgroup analyses explored results in high-risk populations such as pediatric patients, individuals with higher ASA classification, and those with obesity.

Faster Reversal and Fewer Early Complications with Sugammadex

The pooled results showed that sugammadex reverses neuromuscular blockade more effectively than neostigmine. Patients receiving sugammadex:

• Achieved a TOFR ≥ 0.9 more rapidly

• Had shorter extubation times

• Experienced a lower incidence of residual neuromuscular blockade

These advantages were generally consistent across subgroups, with particularly lower heterogeneity in some high-risk categories such as patients with higher ASA class or elevated BMI.

Sugammadex also reduced several important postoperative complications compared with neostigmine, including:

• Postoperative nausea and vomiting (PONV)

• Postoperative pulmonary complications (PPCs)

• Bradycardia

In addition, sugammadex was associated with a significantly lower 30-day readmission rate in the limited number of trials reporting this outcome.

Taken together, these findings support the view that sugammadex improves immediate recovery quality and short-term safety, especially in relation to respiratory and cardiovascular stability.

No Advantage in Length of Stay or Cognitive Outcomes

Despite clear benefits in reversal speed and early complications, sugammadex did not translate into measurable gains in broader recovery metrics. The meta-analysis found no significant differences between sugammadex and neostigmine in:

• Hospital length of stay

• Post-anesthesia care unit (PACU) stay

• Operating room time

• Overall recovery scores

The authors state that:

“This rapid reversal did not lead to significant differences in overall recovery.”

Cognitive outcomes were also carefully evaluated. Seven studies assessed postoperative delirium or postoperative cognitive dysfunction using tools such as the Confusion Assessment Method, MMSE, or MoCA at various postoperative time points. The comparison between sugammadex and neostigmine showed similar rates of cognitive impairment, and neostigmine did not demonstrate improved cognitive outcomes when compared to placebo.

As summarized in the article:

“Both sugammadex and neostigmine appeared to have minimal impact on postoperative cognitive function, with neostigmine showing no substantial improvement in cognitive outcomes.”

Interpreting Heterogeneity and Patient Profiles

The authors acknowledge substantial heterogeneity in key outcomes such as time to TOFR ≥ 0.9 and extubation time. They suggest that factors like age, frailty, ASA classification, and surgical or anesthetic practices likely contribute.

They note that most included patients had ASA class I–II, which may help explain why faster reversal did not change global recovery measures such as hospital stay. Rapid reversal is one element of enhanced recovery, but:

“Although the rapid reversal of neuromuscular blockade is an important component of enhanced recovery, it does not play a decisive role in overall patient recovery.”

This underlines the need for individualized decision-making, especially in frail or high-risk populations where the benefits of faster, more complete reversal may be more pronounced.

Cost, Practice, and Future Research

Sugammadex offers pharmacological and clinical advantages but at a substantially higher price. The article notes that its per-dose cost can be 20 to 30 times higher than neostigmine in some healthcare systems, directly increasing perioperative expenses. While faster recovery and fewer complications may mitigate some costs in selected groups, robust cost-effectiveness analyses are still lacking.

The authors conclude that:

“When economic considerations are set aside, sugammadex appears to offer a safer and more effective pathway for patient recovery than neostigmine… These findings highlight the clinical advantages of sugammadex while underscoring the need for further research to evaluate its cost-effectiveness and its potential influence on long-term recovery outcomes.”

For researchers and clinicians, this meta-analysis provides a detailed evidence base: sugammadex clearly improves the quality and safety of early neuromuscular recovery, but its role in overall recovery pathways and health-economic strategies still requires careful, context-specific evaluation.

 

The translation of the preceding English text in Chinese:

 

为什么麻醉后需要使用拮抗药物

全身麻醉每年用于数以亿计的手术中，而神经肌肉阻滞剂（NMBAs）对于安全插管和提供良好的手术条件至关重要。

当 NMBAs 的作用在手术后持续存在时，患者可能会出现残余神经肌肉阻滞（RNB）。RNB 与术后肺部并发症、更高的死亡率、延长的住院时间、增加的医疗费用以及更大的整体医疗负担相关。

即使是轻度的残余肌无力，也会降低呼吸功能、吞咽能力和气道保护。这些问题在老年患者中特别值得关注，因为他们面临更高的肺炎、误吸和肺不张风险。因此，预防 RNB 是现代麻醉实践中的核心安全目标。

新斯的明与舒更德司：两种不同的策略

新斯的明是一种胆碱酯酶抑制剂，长期以来一直是标准的 NMBA 拮抗剂。它可以加速神经肌肉阻滞的恢复，但即便使用新斯的明，大约 40% 的患者仍会出现残余阻滞，使许多患者仍然面临可避免的术后风险。

舒更德司于 2008 年推出，代表了一种不同的方式。它是一种伽马环糊精，可选择性结合罗库溴铵，使神经肌肉阻滞能够迅速而完全地逆转，而且不会对上气道扩张肌产生负面影响。研究显示，舒更德司在达到安全恢复常用指标——Train-of-Four 比率（TOFR）> 0.9 方面比新斯的明更有效。

尽管具备这些优势，但舒更德司在更广泛临床结局上的影响仍不明确。现有研究和荟萃分析常集中于肺部并发症、PONV 或 TOF 恢复等单一指标，结果往往不一致或难以得出明确结论。关于高风险人群、整体恢复和认知结局等问题仍未得到充分解答。

这项新荟萃分析的目的与规模

为弥补这些空白，Ni Zhu 和 Yongli Li 进行了系统综述和荟萃分析，比较在全麻手术后恢复的患者中舒更德司与新斯的明的效果。

他们这样描述研究目标：

“本研究系统地评估神经肌肉阻滞拮抗剂对术后并发症和恢复质量的影响。”

作者检索了截至 2025 年 4 月的主要医学数据库，并应用了预设的纳入标准。最终共纳入：

• 35 项随机对照试验（4,275 名患者）

• 2 项回顾性研究（49,642 名参与者）

分析集中于需要逆转神经肌肉阻滞的全麻患者。舒更德司试验的对照为新斯的明；新斯的明试验的对照为安慰剂或无活性拮抗剂的标准护理。

研究涵盖多个领域的结局指标：逆转速度、术后并发症、恢复时间、认知功能以及 30 天再入院率。亚组分析涉及高风险人群，如儿童、ASA 分级较高者以及肥胖患者。

舒更德司实现更快逆转并减少早期并发症

综合结果显示，舒更德司在逆转神经肌肉阻滞方面比新斯的明更有效。接受舒更德司的患者：

• 更快达到 TOFR ≥ 0.9

• 拔管时间更短

• 残余神经肌肉阻滞发生率更低

这些优势在多个亚组中保持一致，尤其是在 ASA 分级较高或 BMI 较高等部分高风险群体中表现出较低的异质性。

与新斯的明相比，舒更德司还减少了多项重要的术后并发症，包括：

• 术后恶心呕吐（PONV）

• 术后肺部并发症（PPCs）

• 心动过缓

此外，在报告该指标的少量研究中，舒更德司显著降低了 30 天再入院率。

这些发现整体支持这样一个观点：舒更德司可改善早期恢复质量，提高短期安全性，尤其是在呼吸和心血管稳定性方面。

住院时长与认知结局无明显优势

尽管舒更德司在逆转速度和早期并发症方面具有明确优势，但并未带来整体恢复指标上的改善。荟萃分析显示，舒更德司与新斯的明在以下方面无显著差异：

• 住院时长

• 麻醉后护理单元（PACU）停留时间

• 手术室时间

• 整体恢复评分

作者指出：

“这种快速逆转并未导致整体恢复有显著差异。”

认知结局也得到了仔细评估。七项研究使用 CAM、MMSE 或 MoCA 等工具，在不同术后时间点评估术后谵妄或认知功能障碍。舒更德司与新斯的明的认知损害发生率相似，而新斯的明相比安慰剂也未表现出认知改善。

文章总结道：

“舒更德司和新斯的明对术后认知功能的影响都很小，新斯的明也未显示出显著的认知改善。”

解读异质性与患者差异

作者指出，在 TOFR ≥ 0.9 所需时间和拔管时间等关键结局中存在较大异质性。他们认为年龄、虚弱程度、ASA 分级以及手术或麻醉实践等因素可能起重要作用。

他们注意到，大多数纳入患者的 ASA 分级为 I–II，这可能解释了为何逆转更快并未带来住院时长等宏观恢复指标的变化。快速逆转固然重要，但：

“虽然神经肌肉阻滞的快速逆转是加速康复的重要组成部分，但它并非决定整体恢复的关键因素。”

这说明在虚弱或高风险人群中，更快速且更完全的逆转可能更具临床意义。

成本、实践与未来研究

舒更德司具备明显的药理与临床优势，但价格要高得多。在一些医疗体系中，其单剂量价格可能是新斯的明的 20 至 30 倍，从而直接增加围术期成本。虽然在特定人群中更快的恢复和更少的并发症可能部分抵消成本，但仍需要更系统的成本效益研究。

作者总结道：

“在不考虑经济因素时，舒更德司似乎比新斯的明为患者提供了更安全、更有效的恢复路径……这些发现强调了舒更德司的临床优势，同时也凸显了进一步开展成本效益研究及评估其对长期恢复影响的必要性。”

对于研究者和临床医生而言，这项荟萃分析提供了详细的证据基础：舒更德司确实改善了早期神经肌肉恢复的质量与安全性，但其在整体恢复路径与健康经济策略中的定位仍需根据具体情况谨慎评估。

---

Reference:

Ni Zhu, Yongli Li

Sugammadex vs neostigmine in post-anesthesia recovery: A systematic review and meta-analysis.

Biomol Biomed [Internet]. 2025 Aug. 2 [cited 2025 Dec. 8];26(2):295–306.

Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12689

---

Additional information:

We invite submissions for our upcoming thematic issues, including:

• Immune Prediction and Prognostic Biomarkers in Immuno-Oncology
• Artificial Intelligence and Machine Learning in disease diagnosis and treatment target identification

More news: Blog

Editor: Merima Hadžić